Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Goodman

Showing results (861-870 of 1,119) with videos related to

Pageof 112
Sort By:
CJC Open|February 24, 2022
Prevalence of Cardiovascular Disease in a Population-Based Cohort of High-Cost Healthcare Services UsersPadma Kaul, Nathan Klassen, Douglas C Dover, et al.
American Heart Journal|May 27, 2026
Design of VICTORION-2 Prevent: a randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular diseasePh Gabriel Steg, Shaun G Goodman, J Wouter Jukema, et al.
Nature Communications|September 9, 2015
In vivo capture and label-free detection of early metastatic cellsSamira M Azarin, Ji Yi, Robert M Gower, et al.
The Canadian Journal of Cardiology|December 7, 2007
Missed opportunities for the secondary prevention of cardiovascular disease in CanadaDaniel G Hackam, Lawrence A Leiter, Andrew T Yan, et al.
Journal of the American College of Cardiology|July 30, 2021
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL CholesterolGregory G Schwartz, Michael Szarek, Vera A Bittner, et al.
The Canadian Journal of Cardiology|October 19, 2015
The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation PatientsPaul Angaran, Paul Dorian, Mary K Tan, et al.
Journal of the American Heart Association|September 13, 2023
Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES TrialShaun G Goodman, Philippe Gabriel Steg, Yann Poulouin, et al.
Journal of Thrombosis and Thrombolysis|November 25, 2017
Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCIAndrew Yang, Quin Pon, Andrea Lavoie, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|April 28, 2016
Radial versus femoral access for percutaneous coronary intervention in ST-elevation myocardial infarction patients treated with fibrinolysis: Results from the randomized routine early invasive clinical trialsJohn J Graham, Andrew T Yan, Mary K Tan, et al.
The Canadian Journal of Cardiology|December 2, 2011
Reperfusion strategies and outcomes of ST-segment elevation myocardial infarction patients in Canada: observations from the Global Registry of Acute Coronary Events (GRACE) and the Canadian Registry of Acute Coronary Events (CANRACE)Andrew Czarnecki, Robert C Welsh, Raymond T Yan, et al.
Pageof 112

Showing results (861-870 of 1,119) with videos related to

Sort By:
Pageof 112
CJC Open|February 24, 2022
Prevalence of Cardiovascular Disease in a Population-Based Cohort of High-Cost Healthcare Services UsersPadma Kaul, Nathan Klassen, Douglas C Dover, et al.
American Heart Journal|May 27, 2026
Design of VICTORION-2 Prevent: a randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular diseasePh Gabriel Steg, Shaun G Goodman, J Wouter Jukema, et al.
Nature Communications|September 9, 2015
In vivo capture and label-free detection of early metastatic cellsSamira M Azarin, Ji Yi, Robert M Gower, et al.
The Canadian Journal of Cardiology|December 7, 2007
Missed opportunities for the secondary prevention of cardiovascular disease in CanadaDaniel G Hackam, Lawrence A Leiter, Andrew T Yan, et al.
Journal of the American College of Cardiology|July 30, 2021
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL CholesterolGregory G Schwartz, Michael Szarek, Vera A Bittner, et al.
The Canadian Journal of Cardiology|October 19, 2015
The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation PatientsPaul Angaran, Paul Dorian, Mary K Tan, et al.
Journal of the American Heart Association|September 13, 2023
Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES TrialShaun G Goodman, Philippe Gabriel Steg, Yann Poulouin, et al.
Journal of Thrombosis and Thrombolysis|November 25, 2017
Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCIAndrew Yang, Quin Pon, Andrea Lavoie, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|April 28, 2016
Radial versus femoral access for percutaneous coronary intervention in ST-elevation myocardial infarction patients treated with fibrinolysis: Results from the randomized routine early invasive clinical trialsJohn J Graham, Andrew T Yan, Mary K Tan, et al.
The Canadian Journal of Cardiology|December 2, 2011
Reperfusion strategies and outcomes of ST-segment elevation myocardial infarction patients in Canada: observations from the Global Registry of Acute Coronary Events (GRACE) and the Canadian Registry of Acute Coronary Events (CANRACE)Andrew Czarnecki, Robert C Welsh, Raymond T Yan, et al.
Pageof 112